Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Resveratrol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Spartan Capital Securities
Deal Size : $15.0 million
Deal Type : Public Offering
Neuro-inflammation Biotech Jupiter Neurosciences Revises Terms Ahead Of $15 million IPO
Details : Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.
Brand Name : Jotrol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 02, 2022
Lead Product(s) : Resveratrol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Spartan Capital Securities
Deal Size : $15.0 million
Deal Type : Public Offering
Lead Product(s) : Resveratrol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation
Details : The U.S. patent covers the suspension of active ingredient resveratrol and other compounds in a micellar emulsion that can be delivered via oral capsule.
Brand Name : Jotrol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Lead Product(s) : Resveratrol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Resveratrol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : $1.7 million
Deal Type : Funding
Jupiter Orphan Announces Federal Grant to ADVANCE JOTROL™ to Phase I Clinical Trial for Alzheimer's
Details : The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.
Brand Name : Jotrol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2020
Lead Product(s) : Resveratrol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : $1.7 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?